Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2024-01-02 · accession 0001396814-24-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-04 | 2024-01-02 | PCRX | SLONIN JONATHAN | Chief Medical Off | A - Grant | $0.00 | +5,000 | 51.2K | +11% | $0 |
| D | 2024-01-04 | 2024-01-03 | PCRX | SLONIN JONATHAN | Chief Medical Off | A - Grant | $0.00 | +10.0K | 10.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | A | A | 5,000 | $0.00 | 51,196.48 | D | — | — | (F1) Represents restricted stock units that vest in four equal annual installments beginning on January 2, 2025, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. (F2) Includes 311.535 shares of common stock acquired under the issuer's employee stock purchase plan in December 2023. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-01-03 | A | A | 10,000 | $0.00 | 10,000 | D | $32.07 · — to 2034-01-03 | 10,000 Common Stock | (F3) The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |